• RxSight cut 2026 sales guidance to $110-$120 million from $120-$135 million; raised gross margin outlook to 73%-75% from 70%-72%.
• Forecast 2026 revenue of $140-$160 million, including $30-$40 million from its Alcon collaboration.
• Kept operating expense outlook at the high end of $150-$160 million.
• Preliminary Q2 revenue seen at $32-$34 million, including $5-$7 million from the Alcon collaboration.
• Q2 sales seen at about $27 million on 24,917 LAL units, 11 LDD units; cash about $209 million at June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RxSight Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607061615PRIMZONEFULLFEED9757583) on July 06, 2026, and is solely responsible for the information contained therein.